Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting
Martina Imbimbo,Jean-Michel Maury,Marina Garassino,Nicolas Girard,RARECAREnet Working Group,Monika Hackl,Elizabeth Van Eycken,Kris Henau,Nadya Dimitrova,Mario Sekerija,Ladislav Dušek,Margit Mägi,Nea Malila,Maarit Leinonen,Michel Velten,Xavier Troussard,Veronique Bouvier,Anne-Valérie Guizard,Anne-Marie Bouvier,Patrick Arveux,Marc Maynadié,Anne-Sophie Woronoff,Michel Robaszkiewicz,Isabelle Baldi,Alain Monnereau,Brigitte Tretarre,Marc Colonna,Florence Molinié,Simona Bara,Claire Schvartz,Bénédicte Lapôtre-Ledoux,Pascale Grosclaude,Roland Stabenow,Sabine Luttmann,Alice Nennecke,Jutta Engel,Gabriele Schubert-Fritschle,Jan Heidrich,Bernd Holleczek,Jón Gunnlaugur Jónasson,Kerri Clough-Gorr,Harry Comber,Guido Mazzoleni,Adriano Giacomin,Antonella Sutera Sardo,Alessandro Barchielli,Diego Serraino,Roberta De Angelis,Sandra Mallone,Andrea Tavilla,Daniela Pierannunzio,Silvia Rossi,Mariano Santaquilani,Arnold Knijn,Fabio Pannozzo,Valerio Gennaro,Lucia Benfatto,Paolo Ricci,Mariangela Autelitano,Gianbattista Spagnoli,Mario Fusco,Mario Usala,Francesco Vitale,Maria Michiara,Rosario Tumino,Lucia Mangone,Fabio Falcini,Stefano Ferretti,Rosa Angela Filiberti,Enza Marani,Arturo Iannelli,Flavio Sensi,Silvano Piffer,Maria Gentilini,Anselmo Madeddu,Antonio Ziino,Sergio Maspero,Pina Candela,Fabrizio Stracci,Giovanna Tagliabue,Massimo Rugge,Annalisa Trama,Gemma Gatta,Laura Botta,Riccardo Capocaccia,Santa Pildava,Giedre Smailyte,Neville Calleja,Tom Børge Johannesen,Jadwiga Rachtan,Stanisław Góźdź,Jerzy Błaszczyk,Kamila Kępska,Gonçalo Forjaz de Lacerda,Maria José Bento,Ana Miranda,Chakameh Safaei Diba,Enrique Almar,Nerea Larrañaga,Arantza Lopez de Munain,Ana Torrella-Ramos,José María Díaz García,Rafael Marcos-Gragera,Maria Josè Sanchez,Carmen Navarro,Diego Salmeron,Conchi Moreno-Iribas,Jaume Galceran,Marià Carulla,Mohsen Mousavi,Christine Bouchardy,Silvia M Ess,Andrea Bordoni,Isabelle Konzelmann,Jem Rashbass,Anna Gavin,David H Brewster,Dyfed Wyn Huws,Otto Visser,Magdalena Bielska-Lasota,Maja Primic-Zakelj,Ian Kunkler,Ellen Benhamou
DOI: https://doi.org/10.1016/j.ejso.2018.01.078
Abstract:The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of databases, translational research programs, and clinical trials. Access to innovative strategies represents a major challenge, as there is a lack of funding for clinical research in rare cancers and their rarity precludes the design of robust clinical trials that could lead to specific approval of drugs. In this context, patient-centered initiatives, such as the establishment of dedicated networks, are warranted. International societies, such as IMIG (International Mesothelioma Interest Group) and ITMIG (International Thymic Malignancy Interest Group) provide infrastructure for global collaboration, and there are many advantages to having strong regional groups working on the same issues. There may be regional differences in risk factors, susceptibility, management and outcomes. The ability to address questions both regionally as well as globally is ideal to develop a full understanding of mesothelioma and thymic malignancies. In Europe, through the integration of national networks with EURACAN, the collaboration with academic societies and international groups, the development of networks in thoracic oncology provides multiplex integration of clinical care and research, ultimately ensuring equal access to high quality care to all patients, with the opportunity of conducting high level clinical and translational research projects.